We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FitLife Brands (FTLF) Surges 13.1%: Is This an Indication of Further Gains?
Read MoreHide Full Article
FitLife Brands Inc. (FTLF - Free Report) shares soared 13.1% in the last trading session to close at $13.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 12.7% loss over the past four weeks.
FitLife scored a strong price increase, on investors’ optimism, driven by the reports of director Todd Ordal purchasing 300 shares of the company on April 15 at $12.07 per share. This followed just a day after another FTLF director, Matthew Lingenbrink acquired 3000 shares for approximately $36,510.
This company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $15.84 million, down 4.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For FitLife Brands, the consensus EPS estimate for the quarter has been revised 100% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on FTLF going forward to see if this recent jump can turn into more strength down the road.
FitLife Brands belongs to the Zacks Medical - Products industry. Another stock from the same industry, LeMaitre Vascular (LMAT - Free Report) , closed the last trading session 1.9% higher at $86.28. Over the past month, LMAT has returned -0.2%.
For LeMaitre, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.50. This represents a change of +13.6% from what the company reported a year ago. LeMaitre currently has a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FitLife Brands (FTLF) Surges 13.1%: Is This an Indication of Further Gains?
FitLife Brands Inc. (FTLF - Free Report) shares soared 13.1% in the last trading session to close at $13.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 12.7% loss over the past four weeks.
FitLife scored a strong price increase, on investors’ optimism, driven by the reports of director Todd Ordal purchasing 300 shares of the company on April 15 at $12.07 per share. This followed just a day after another FTLF director, Matthew Lingenbrink acquired 3000 shares for approximately $36,510.
This company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $15.84 million, down 4.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For FitLife Brands, the consensus EPS estimate for the quarter has been revised 100% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on FTLF going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
FitLife Brands belongs to the Zacks Medical - Products industry. Another stock from the same industry, LeMaitre Vascular (LMAT - Free Report) , closed the last trading session 1.9% higher at $86.28. Over the past month, LMAT has returned -0.2%.
For LeMaitre, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.50. This represents a change of +13.6% from what the company reported a year ago. LeMaitre currently has a Zacks Rank of #2 (Buy).